Synovial tissues concentrate secreted APRIL

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  Gabay, Cem ^a,b   Krenn, Veit ^c   Bosshard, Carine ^b,d   Seemayer, Christian A ^b,e   Chizzolini, Carlo ^d   Huard, Bertrand ^b,d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c Histology Center   (Germany)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ANIMAL CELL; ARTICLE; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FENESTRATION; GOUT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYME DISEASE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PLASMA CELL; PROTEIN SECRETION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIUM; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; SECRETION;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUTROPHILS; PLASMA CELLS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 75649150470     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2817     Document Type: Article

References (43)

1. Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999, 65:680-683.
2. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829. 10.1038/ni829, 12154359.
3. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK, Mizoguchi E, Geha RS. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004, 101:3903-3908. 10.1073/pnas.0307348101, 374342, 14988498.
4. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, Shan M, Chadburn A, Villanacci V, Plebani A, Knowles DM, Rescigno M, Cerutti A. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007, 26:812-826. 10.1016/j.immuni.2007.04.014, 17570691.
5. Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 2007, 109:2961-2967.
6. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, Dobles M, Scott ML, Maquelin A, Belnoue E, Siegrist CA, Chevrier S, Acha-Orbea H, Leung H, Mackay F, Tschopp J, Schneider P. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008, 111:1004-1012. 10.1182/blood-2007-09-110874, 17942754.
7. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008, 111:2755-2764. 10.1182/blood-2007-09-110858, 18180376.
8. Huard B, McKee T, Bosshard C, Durual S, Matthes T, Myit S, Donze O, Frossard C, Chizzolini C, Favre C, Zubler R, Guyot JP, Schneider P, Roosnek E. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 2008, 118:2887-2895. 2447926, 18618015.
9. Planelles L, Castillo-Gutierrez S, Medema JP, Morales-Luque A, Merle-Beral H, Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 2007, 92:1284-1285. 10.3324/haematol.10317, 17768131.
10. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, Tschopp J, Donze O, Le Gal FA, Huard B. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 2007, 109:331-338. 10.1182/blood-2006-02-001800, 17190854.
11. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007, 179:7276-7286.
12. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, Rennert PD, Tschopp J, Schneider P. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005, 201:1375-1383. 10.1084/jem.20042309, 2213192, 15851487.
13. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, Medema JP. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005, 12:637-648. 10.1038/sj.cdd.4401647, 15846369.
14. Bischof D, Elsawa SF, Mantchev G, Yoon J, Michels GE, Nilson A, Sutor SL, Platt JL, Ansell SM, von Bulow G, Bram RJ. Selective activation of TACI by syndecan-2. Blood 2006, 107:3235-3242. 10.1182/blood-2005-01-0256, 1895754, 16357320.
15. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005, 8:243-265. full_text, 15564724.
16. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264. 10.1146/annurev.immunol.21.120601.141152, 12427767.
17. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15:289-302. 10.1016/S1074-7613(01)00183-2, 11520463.
18. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001, 2:632-637. 10.1038/89782, 11429548.
19. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, Weyand CM. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005, 115:3083-3092. 10.1172/JCI25265, 1257539, 16239971.
20. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008, 58:61-72. 10.1002/art.23178, 18163485.
21. Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008, 48:406-417. 10.1177/0091270008315312, 18303125.
22. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005, 174:864-870.
23. Nagatani K, Itoh K, Nakajima K, Kuroki H, Katsuragawa Y, Mochizuki M, Aotsuka S, Mimori A. Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL. Arthritis Rheum 2007, 56:3554-3563. 10.1002/art.22929, 17968879.
24. Magalhaes R, Stiehl P, Morawietz L, Berek C, Krenn V. Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows Arch 2002, 441:415-427. 10.1007/s00428-002-0702-1, 12447670.
25. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55-78. 10.1016/0049-0172(73)90035-8, 4581554.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
27. Kim HJ, Krenn V, Steinhauser G, Berek C. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol 1999, 162:3053-3062.
28. Bradfield PF, Scheiermann C, Nourshargh S, Ody C, Luscinskas FW, Rainger GE, Nash GB, Miljkovic-Licina M, Aurrand-Lions M, Imhof BA. JAM-C regulates unidirectional monocyte transendothelial migration in inflammation. Blood 2007, 110:2545-2555. 10.1182/blood-2007-03-078733, 1988941, 17625065.
29. Pradet-Balade B, Medema JP, Lopez-Fraga M, Lozano JC, Kolfschoten GM, Picard A, Martinez AC, Garcia-Sanz JA, Hahne M. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 2002, 21:5711-5720. 10.1093/emboj/cdf565, 131062, 12411489.
30. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002, 169:4314-4321.
31. Levick JR, McDonald JN. Fluid movement across synovium in healthy joints: role of synovial fluid macromolecules. Ann Rheum Dis 1995, 54:417-423. 10.1136/ard.54.5.417, 1005608, 7794053.
32. Haywood L, Walsh DA. Vasculature of the normal and arthritic synovial joint. Histol Histopathol 2001, 16:277-284.
33. Watanabe R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Kuwano Y, Tada Y, Maruyama N, Okochi H, Tamaki K. Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid. J Dermatol Sci 2007, 46:53-60. 10.1016/j.jdermsci.2006.12.008, 17250993.
34. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmstrom V. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R167. 10.1186/ar2076, 1794511, 17092341.
35. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003, 48:982-992. 10.1002/art.10860, 12687540.
36. Schaller M, Stohl W, Tan SM, Benoit VM, Hilbert DM, Ditzel HJ. Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis. Ann Rheum Dis 2005, 64:743-749. 10.1136/ard.2004.025502, 1755497, 15458959.
37. Roosnek E, Burjanadze M, Dietrich PY, Matthes T, Passweg J, Huard B. Tumors that look for their springtime in APRIL. Crit Rev Oncol Hematol 2009,
38. Wegrowski Y, Milard AL, Kotlarz G, Toulmonde E, Maquart FX, Bernard J. Cell surface proteoglycan expression during maturation of human monocytes-derived dendritic cells and macrophages. Clin Exp Immunol 2006, 144:485-493. 10.1111/j.1365-2249.2006.03059.x, 1941969, 16734618.
39. Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, Huard B. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 2006, 80:697-704. 10.1189/jlb.1105655, 16793914.
40. Schwaller J, Went P, Matthes T, Dirnhofer S, Donze O, Mhawech-Fauceglia P, Myit S, Huard B. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia 2007, 21:1324-1327. 10.1038/sj.leu.2404627, 17315017.
41. Patterson AM, Gardner L, Shaw J, David G, Loreau E, Aguilar L, Ashton BA, Middleton J. Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. Arthritis Rheum 2005, 52:2331-2342. 10.1002/art.21222, 16052590.
42. Orlovskaya GV, Muldiyarov PY, Kazakova IS. Synovial plasma cells in rheumatoid arthritis. Electron microscope and immunofluorescence studies. Ann Rheum Dis 1970, 29:524-532. 10.1136/ard.29.5.524, 1010567, 4097692.
43. Santiago B, Baleux F, Palao G, Gutierrez-Canas I, Ramirez JC, Arenzana-Seisdedos F, Pablos JL. CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans. Arthritis Res Ther 2006, 8:R43. 10.1186/ar1900, 1526602, 16507142.